Weber F, Bohrmann B, Niewoehner J, Fischer JA, Rueger P, Tiefenthaler G, Moelleken J, Bujotzek A, Brady K, Singer T, Ebeling M, Iglesias A, Freskgård PO. Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode. Cell Rep. 2018 Jan 2;22(1):149-162. PubMed.

Recommends

Please login to recommend the paper.

Comments

  1. While the details of the immunology and immunochemistry involved are rather outside my area of experience and expertise, I found this paper very interesting to read. It is fascinating that the authors could attach the Brain Shuttle molecule at the C terminal end of a conventional monoclonal antibody and that this arrangement does not interfere with FcγR binding. This modification to the monoclonal antibody also had the effect of abrogating adverse reactions in the periphery. This fundamental work has very important implications for increasing the efficiency and safety of antibody treatments for CNS disorders, particularly Alzheimer's disease.

    View all comments by Roy Weller

Make a Comment

To make a comment you must login or register.